StockData
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. (AQST) stock

AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 3/30
$3.78+0.08 (+2.16%)

Close on Nov 18, 2026Market cap $474.43MP/E –Yield –

Aquestive Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Aquestive Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$52.75M. For fiscal 2025 it was -$71.05M. The highest annual figure on record is -$113.00K in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$71.05M–
FY2024Dec 31, 2024-$30.77M–
FY2023Dec 31, 2023-$15.10M–
FY2022Dec 31, 2022-$42.07M–
FY2021Dec 31, 2021-$34.68M–
FY2020Dec 31, 2020-$42.89M–
FY2019Dec 31, 2019-$52.67M–
FY2018Dec 31, 2018-$48.93M–
FY2017Dec 31, 2017-$113.00K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$8.22M–
Q1 FY2026Mar 31, 2026-$4.20M–
Q4 FY2025Dec 31, 2025-$28.84M–
Q3 FY2025Sep 30, 2025-$11.48M–
Q2 FY2025Jun 30, 2025-$11.37M-20769.1%
Q1 FY2025Mar 31, 2025-$19.37M–
Q4 FY2024Dec 31, 2024-$13.58M–
Q3 FY2024Sep 30, 2024-$8.29M–
Q2 FY2024Jun 30, 2024$55.00K–
Q1 FY2024Mar 31, 2024-$8.96M–
Q4 FY2023Dec 31, 2023-$3.91M–
Q3 FY2023Sep 30, 2023-$2.38M–
Q2 FY2023Jun 30, 2023-$4.21M–
Q1 FY2023Mar 31, 2023-$4.61M–
Q4 FY2022Dec 31, 2022-$10.71M–
Q3 FY2022Sep 30, 2022-$8.85M–
Q2 FY2022Jun 30, 2022-$12.76M–
Q1 FY2022Mar 31, 2022-$9.74M–
Q4 FY2021Dec 31, 2021-$11.67M–
Q3 FY2021Sep 30, 2021-$7.97M–
Q2 FY2021Jun 30, 2021-$6.52M-1749.9%
Q1 FY2021Mar 31, 2021-$8.53M–
Q4 FY2020Dec 31, 2020-$15.65M–
Q3 FY2020Sep 30, 2020-$13.78M–
Q2 FY2020Jun 30, 2020$395.00K–
Q1 FY2020Mar 31, 2020-$13.86M–
Q4 FY2019Dec 31, 2019-$9.90M–
Q3 FY2019Sep 30, 2019-$11.00M-307.4%
Q2 FY2019Jun 30, 2019-$18.69M–
Q1 FY2019Mar 31, 2019-$13.07M-225.5%
Q4 FY2018Dec 31, 2018-$12.35M–
Q1 FY2018Mar 31, 2018$5.31M–
Q4 FY2017Dec 31, 2017-$7.26M–
Q3 FY2017Sep 30, 2017$10.42M–
Q2 FY2017Jun 30, 2017-$4.06M–

More Aquestive Therapeutics figures

See a number that looks wrong?